Cash and cash equivalents and marketable securities as of September 30, 2025 were $680.3 million, compared with $661.1 million as of June 30, 2025, which includes net proceeds of approximately $48.7 million from the sale of 1,515,151 shares through the Company’s at-the-market facility based on reverse inquiry from an existing, high-quality fund. Based on current operating plans, the Company expects its existing cash, cash equivalents and marketable securities will be sufficient to fund operations into the first half of 2028.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- enGene price target raised to $10 from $4 at UBS
- Optimistic Growth Potential for CG Oncology, Inc. Driven by Positive Regulatory Precedents and Strategic Pricing
- CG Oncology’s Phase 2 Study: A New Hope for High-Risk NMIBC
- Positive Outlook for CG Oncology: Buy Rating Affirmed Amid Regulatory Progress and Operational Efficiency
- Promising Developments and Market Expansion Potential Drive Buy Rating for CG Oncology, Inc.